These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24000595)

  • 1. [Activating effect of a germanium-organic compound on immunocompetent cells during intranasal immunization of mice with a live influenza vaccine].
    Liashenko VA; Akhmatova NK; Ambrosov IV; Matelo SK; Markushin SG; Akhmatov ÉA; Sukhno AS; Khomenkov VG
    Zh Mikrobiol Epidemiol Immunobiol; 2013; (3):60-8. PubMed ID: 24000595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Activation of lymphocytes under the influence of an influenza vaccine combined with a low molecular weight germanium organic compound].
    Liashenko VA; Akhmatova NK; Ambrosov IV; Matelo SK; Akhmatov ÉA; Sukhno AS; Khomenkov VG
    Zh Mikrobiol Epidemiol Immunobiol; 2012; (6):64-8. PubMed ID: 23297635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
    Wu H; Bao Y; Wang X; Zhou D; Wu W
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
    Asahi-Ozaki Y; Itamura S; Ichinohe T; Strong P; Tamura S; Takahashi H; Sawa H; Moriyama M; Tashiro M; Sata T; Kurata T; Hasegawa H
    Microbes Infect; 2006 Oct; 8(12-13):2706-14. PubMed ID: 16968669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge.
    Wang X; Zhang W; Liu F; Zheng M; Zheng D; Zhang T; Yi Y; Ding Y; Luo J; Dai C; Wang H; Sun B; Chen Z
    Arch Virol; 2012 Aug; 157(8):1451-61. PubMed ID: 22552485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine.
    Asanuma H; Hirokawa K; Uchiyama M; Suzuki Y; Aizawa C; Kurata T; Sata T; Tamura S
    Vaccine; 2001 Jul; 19(28-29):3981-9. PubMed ID: 11427274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests.
    Sasaki E; Kuramitsu M; Momose H; Kobiyama K; Aoshi T; Yamada H; Ishii KJ; Mizukami T; Hamaguchi I
    Vaccine; 2017 Feb; 35(5):821-830. PubMed ID: 28063707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.
    Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ
    Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model.
    Lee TY; Kim CU; Bae EH; Seo SH; Jeong DG; Yoon SW; Chang KT; Kim YS; Kim SH; Kim DJ
    Vaccine; 2017 Jan; 35(4):586-595. PubMed ID: 28024958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Fang F; Zheng M; Chen Z
    Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
    Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
    Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
    Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.
    Zheng M; Liu F; Shen Y; Wang S; Xu W; Fang F; Sun B; Xie Z; Chen Z
    Hum Vaccin Immunother; 2015; 11(2):397-406. PubMed ID: 25607884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
    Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
    Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
    Moriyama M; Chino S; Ichinohe T
    Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.